Here are the top 5 biosimilar articles for the week of December 13, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of December 13, 2021.
Number 5: Tot Biopharm received China regulatory approval for a bevacizumab biosimilar and Fujifilm moves forward with plans for an Innovation and Collaboration Center.
Number 4: In midterm results for a phase 2 study presented at the the 2021 San Antonio Breast Cancer Symposium (SABCS), a trastuzumab biosimilar in conjunction with gedatolisib demonstrated an overall response rate of 58.8% with manageable toxicity in patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (mBC).
Number 3: Researchers who surveyed patients and oncologists about biosimilars and switches to biosimilars from reference products found discrepancies between patients’ perceptions and physician perceptions of whether the information provided was adequate.
Number 2: Ahead of sales and revenues, Icelandic company Alvotech lined up a massive capital investment and an initial public offering (IPO).
Number 1: Long-term survival findings for the trastuzumab biosimilar Ontruzant demonstrated equivalence to the reference product (Herceptin) in a phase 3 study of patients with HER2–positive breast cancer, investigators reported at the 2021 SABCS.
To read all of these articles and more, visit centerforbiosimilars.com.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Survey Finds Korean Oncologists Trust Biosimilars But Prescribe Originators More
May 13th 2024A Korean survey found that while most oncologists believe biosimilars are just as safe and effective as originator drugs, they often prescribe the originators due to factors like lack of patient trust in biosimilars and lower than expected cost savings.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.